ClinicalTrials.gg
RecruitingNCT07611084Updated May 28, 2026

Construction of a Cohort of Elderly Patients With Atrial Fibrillation in Rural China

An observational study in Atrial Fibrillation (AF), Heart Failure and Screening, sponsored by Jiangsu Taizhou People's Hospital. Recruiting at 1 site in China. Open to participants aged 65 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Jiangsu Taizhou People's Hospital · Observational

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,500
Ages
65 Years to 80 Years
Sex
All
01

Study summary

Atrial fibrillation (AF) is a common arrhythmia in aging populations and is strongly associated with an increased risk of heart failure (HF) and adverse cardiovascular outcomes. However, early detection of HF among patients with AF remain inadequate in rural settings. This study aims to screen for HF among older adults with AF in rural China and to conduct long-term follow-up in order to observe the disease progression in patients with AF.

This study will recruit at least 2,500 elderly individuals aged between 65 and 80 years, with confirmed diagnoses of AF, residing in rural areas. Participants will undergo HF screening using NT-proBNP testing and echocardiographic assessment. Additionally, data will be collected on electrocardiographic signals, seismocardiography, voice, and demographic characteristics. Following data collection, participants will be followed up every three months to monitor the incidence and progression of HF as well as the occurrence of adverse cardiovascular events.

02

Conditions studied

  • Atrial Fibrillation (AF)
  • Heart Failure
  • Screening
  • Progression
03

In context

Atrial Fibrillation

4,009 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

This study's planned enrollment of 2,500 is above the median of 300 across 1,400 observational studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

Jiangsu Taizhou People's Hospital is the lead sponsor of 16 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population is rural-dwelling older adults aged 65 to 80 years with confirmed atrial fibrillation in China. Participants are required to undergo heart failure screening and provide informed consent. Individuals with severe comorbidities or conditions that may interfere with study participation will be excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Permanent residents with local household registration in rural China.
  2. Aged 65-80 years.
  3. confirmation of AF or possession of a diagnostic certificate for AF issued by a specialist.
  4. Willing to participate in HF screening.
  5. Ability to understand the study procedures and provide written .

Exclusion criteria

Exclusion Criteria:

  1. Expected of less than 3 months.
  2. Severe renal insufficiency (Ccr \< 30ml/min) or ongoing dialysis treatment.
  3. Cardiac insufficiency secondary to correctable causes, including hyperthyroid heart disease, anemic heart disease, or uncorrected congenital heart disease.
  4. Indications for pacemaker implantation without having undergone implantation.
  5. complicated by type II respiratory failure.
  6. Special populations, including patients with mental illnesses.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Composite endpoint

    a composite of cardiovascular mortality, all strokes (ischemic or hemorrhagic stroke), hospitalization due to worsening of HF or acute coronary syndrome (ACS), and emergency visits due to AF

    Time frame: through study completion, an average of 3 years

07

Study locations

1 of 1 sites recruiting
  • Department of Cardiology
    Taizhou, Jiangsu 225300, China
    Recruiting
08

References and documents

Publications

  • Chu M, Zhang S, Gong J, Yang S, Yang G, Sun X, Wu D, Xia Y, Jiao J, Peng X, Peng Z, Hong L, Wang Z, Li M, Lip GYH, Chen M; MIRACLE-AF Investigators. Telemedicine-based integrated management of atrial fibrillation in village clinics: a cluster randomized trial. Nat Med. 2025 Apr;31(4):1276-1285. doi: 10.1038/s41591-025-03511-2. Epub 2025 Feb 21. PubMed 39984634 ↗

Related links

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD), including baseline characteristics, laboratory results, echocardiographic data, and follow-up outcomes, will be made available upon reasonable request. Data sharing will be subject to approval by the study investigators and in accordance with institutional policies and ethical regulations.

Supporting information: Study protocol, Statistical analysis plan

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07611084
Lead sponsor
Jiangsu Taizhou People's Hospital
Responsible party
Ming Chu (Clinical Professor, Jiangsu Taizhou People's Hospital) — Principal investigator
First posted
May 28, 2026
Start date
Mar 14, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
May 28, 2026

Study contacts

Chuanmeng Zhang, Dr.
Contact
tzyyzcm@njmu.edu.cn
+8615996000626

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion